Evidence map›Paper›PMID 38653503›Full record

ArticleACR open rheumatology2024

Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota.

Kristofer Andréasson, Tor Olofsson, Venu Lagishetty, Zaid Alrawi, Eline Klaassens, Savanne Holster, Roger Hesselstrand, Jonathan P Jacobs, Johan K Wallman, Elizabeth R Volkmann

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACR open rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 3 countries.

Kristofer AndréassonLund University, Lund, Sweden.ORCID https://orcid.org/0000-0001-7021-2541
Tor OlofssonLund University, Lund, Sweden.ORCID https://orcid.org/0000-0002-9919-4487
Venu LagishettyUniversity of California, Los Angeles.ORCID https://orcid.org/0000-0001-6500-8255
Zaid AlrawiLund University, Lund, Sweden.
Eline KlaassensBaseclear B.V, Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-2190-5285
Savanne HolsterBaseclear B.V, Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-4204-6811
Roger HesselstrandLund University, Lund, Sweden.ORCID https://orcid.org/0000-0001-6794-2201
Jonathan P JacobsUniversity of California, Los Angeles and VA Greater Los Angeles Healthcare System.ORCID https://orcid.org/0000-0003-4698-0254
Johan K WallmanLund University, Lund, Sweden.ORCID https://orcid.org/0000-0002-4915-2924
Elizabeth R VolkmannUniversity of California, Los Angeles.ORCID https://orcid.org/0000-0003-3750-6569
University of California, Los Angeles · US

Funding

Identifying predictors of treatment response in systemic sclerosis-related interstitial lung diseaseK23HL150237 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOLKMANN, ELIZABETH R · 2020 to 2024
$910k
Modulation of the Intestinal Microbiome in Obesity by a High Protein DietIK2CX001717 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI JACOBS, JONATHAN PATRICK · 2018 to 2023
–
Anna-Greta Crafoords Stiftelse för Reumatologisk Forskning 20192005CSRD VA IK2 CX001717NHLBI NIH HHS K23 HL150237NHLBI NIH HHS K23HL150237-01Svenska Läkaresällskapet 784201Ulla och Roland Gustafssons Donationsfond
6 · The paper itself

Abstract

objectiveEmerging research suggests that rheumatoid arthritis (RA) is associated with intestinal dysbiosis. This prospective pilot study evaluates changes in intestinal microbial composition in patients with RA initiating treatment with either methotrexate (MTX) or a tumor necrosis factor inhibitor (TNFi).

methodsConsecutive patients, fulfilling the 2010 American College of Rheumatology/EULAR classification criteria for RA, who started treatment with either MTX or TNFi delivered a stool sample upon initiation of immunosuppression and 3 months later. A 16S ribosomal RNA gene-based validated microbiota test (GA-map Dysbiosis Index Score [DIS], Genetic Analysis, Oslo, Norway) was used to evaluate for the presence and degree of dysbiosis. Fecal levels of Prevotella copri (P. copri) were analyzed by custom-made quantitative polymerase chain reaction. Changes in microbial composition were analyzed in relation to changes in disease activity, as measured by the disease activity score based on 28-joint counts, using C-reactive protein.

resultsAt baseline, dysbiosis was present in 33 of 50 (66%) participants and more common in participants with more than 2 years of disease duration (P = 0.019). At the 3-month follow-up, 27 of 50 (54%) were good treatment responders and the DIS had improved in 14 of 50 (28%). Participants initiating TNFi more often exhibited improvement in the DIS compared with those initiating MTX (P = 0.031). P. copri was identified in 32 of 50 (64%) at baseline. An improvement in disease activity score based on 28-joint counts, using C-reactive protein was associated with a simultaneous decrease in P. copri abundance (r

conclusionThis study affirms that dysbiosis is a feature of RA. Although patients were not randomized to MTX or TNFi, the findings suggest that specific therapies may differentially modulate the gastrointestinal microbiota in RA. The association between P. copri and treatment response requires further study.

Identifiers

PMID38653503
PMCPMC11246830
OpenAlexW4395081030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.